Although it can be prevented and successfully treated, tuberculosis (TB) is the world’s deadliest infectious disease: in 2015, 1.8 million people died from it. While there have been substantial and important innovations in the fight against TB, including faster, more accurate diagnostic tests and the first new medicines in nearly 50 years, deadly gaps remain in implementing and providing access to these advances.
The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.
It provides advice to any MSF, PIH and IRD projects for individual patient’s management on a case-by-case basis in answer to requests initiated by clinicians from the projects.
For more information, please download the terms of reference.
An overview of MSF’s programmatic use and clinical research with new TB treatment regimens.
Pharmacovigilance forms and other resources for staff on endTB sites.
This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.
This MSF Access Campaign report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.
We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
This report was produced with endTB's support.